lilly glp 1 weight loss Eli drug tirzepatide data released Eli Lilly, Novo Nordisk expand

Present alternatives with data, not opinions

The FDA warns that these products are of unknown quality and may be harmful

An optimized GLP-1/CCK fusion had enhanced efficacy to lower body weight in obese rodents relative to mono-agonist controls and their co-administration [946,947]

27 Higher doses of tirzepatide were noted to significantly ameliorate biomarkers related to fatty liver while increasing adiponectin levels in T2DM

nevertheless, patients transitioned to liraglutide sustained efficacy irrespective of antibody status (Garber 2011)

Patients could save up to $500 to $800 per month with this new price model